Calliditas Therapeutics AB (NAS:CALT)
$ 21.9 -0.1 (-0.45%) Market Cap: 587.80 Mil Enterprise Value: 582.30 Mil PE Ratio: 0 PB Ratio: 18.56 GF Score: 49/100

Q1 2021 Calliditas Therapeutics AB Earnings Call Transcript

May 18, 2021 / 12:30PM GMT
Release Date Price: $29.08 (-0.14%)
Operator

Ladies and gentlemen, welcome to the Calliditas Therapeutics Q1 2021 Conference. (Operator Instructions)

I'll now hand the floor to CEO, Renee Lucander. Please begin your meeting.

Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Thank you, and welcome to this Q1 2021 report from Calliditas. If you turn to Page 2, and before we begin, giving our listing on NASDAQ Global Select, I would just like to draw your attention to the forward-looking statements.

So turning to Page 3. In Q1, the company reached a major milestone with a filing for approval in IgA nephropathy with the FDA. This is the first-ever submission for proven IgAN, and it provides for thousands of patients living every day with this progressive disease. We subsequently received priority review from the FDA, and we're also granted accelerated assessment by EMA in April.

We continue to deliver on our plan, and we will submit our dossier to EMA this quarter, as previously announced, and we're very excited to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot